Advanced search
Add to list

DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.

(2008) EJC SUPPLEMENTS. 6(12). p.33-33
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
De Roock, W et al. “DUSP4 Expression Level in Colorectal Primaries Predicts Overall Survival Benefit in Kras Wild-type and Kras Mutant Colorectal Cancer After Treatment with Cetuximab for Metastatic Disease.” Ejc Supplements. Vol. 6. 2008. 33–33. Print.
APA
De Roock, W., Janssens, M., Biesmans, B., Jacobs, B., De Schutter, J., Humblet, Y., Peeters, M., et al. (2008). DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease. EJC SUPPLEMENTS (Vol. 6, pp. 33–33). Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Chicago author-date
De Roock, W, M Janssens, B Biesmans, B Jacobs, J De Schutter, Y Humblet, Marc Peeters, E Van Cutsem, P Marynen, and S Tejpar. 2008. “DUSP4 Expression Level in Colorectal Primaries Predicts Overall Survival Benefit in Kras Wild-type and Kras Mutant Colorectal Cancer After Treatment with Cetuximab for Metastatic Disease.” In Ejc Supplements, 6:33–33.
Chicago author-date (all authors)
De Roock, W, M Janssens, B Biesmans, B Jacobs, J De Schutter, Y Humblet, Marc Peeters, E Van Cutsem, P Marynen, and S Tejpar. 2008. “DUSP4 Expression Level in Colorectal Primaries Predicts Overall Survival Benefit in Kras Wild-type and Kras Mutant Colorectal Cancer After Treatment with Cetuximab for Metastatic Disease.” In Ejc Supplements, 6:33–33.
Vancouver
1.
De Roock W, Janssens M, Biesmans B, Jacobs B, De Schutter J, Humblet Y, et al. DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease. EJC SUPPLEMENTS. 2008. p. 33–33.
IEEE
[1]
W. De Roock et al., “DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.,” in EJC SUPPLEMENTS, Geneva, 2008, vol. 6, no. 12, pp. 33–33.
@inproceedings{687903,
  author       = {De Roock, W and Janssens, M and Biesmans, B and Jacobs, B and De Schutter, J and Humblet, Y and Peeters, Marc and Van Cutsem, E and Marynen, P and Tejpar, S},
  booktitle    = {EJC SUPPLEMENTS},
  issn         = {1359-6349},
  language     = {eng},
  location     = {Geneva},
  number       = {12},
  pages        = {33--33},
  title        = {DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.},
  volume       = {6},
  year         = {2008},
}

Web of Science
Times cited: